Definium's Phase 3 Emerge study of DT120 (LSD) meets primary endpoint in major depression

Definium Therapeutics, Inc. (formerly MindMed) (DFTX) — Definium Therapeutics, the rebranded MindMed, reported positive topline results from its pivotal Phase 3 Emerge study of DT120 (formerly MM120, an LSD orally disintegrating tablet) in major depressive disorder.

A single 100 microgram dose delivered an 8.1-point placebo-adjusted MADRS improvement at Week 6 (p<0.0001) and a 7.3-point advantage at Week 12, with no serious adverse events or suicidality signal. The readout is the first positive randomized Phase 3 result for a single-dose lysergide compound in a major psychiatric indication, materially de-risking the company's lead program.

Source: businesswire.com

For the rest of that week's sector news, read our week in review.